Survodutide
SYNCHRONIZE™-2
Boehringer Ingelheim · Phase 3 · Completed · Enrollment 755
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Survodutide 3.6 mg | Obesity + T2D | 3.6 mg | n/r | n/r | n/r |
| Survodutide 6.0 mg | Obesity + T2D | 6.0 mg | n/r | n/r | n/r |
| Placebo | Obesity + T2D | n/r | n/r | n/r | n/r |